|
4XI2
Crystal Structure of an auto-inhibited form of Bruton's Tryrosine Kinase
提交 2015-01-06
|
构建体不同
突变/修饰不同
聚集状态不同
配体/离子不同
实验环境不同
结构质量不同
|
Assembly 1
蛋白同源多聚体
同源多聚体;蛋白 × 2
PDB 声明:dimeric
|
链 A
214–659(446 aa)
片段:UNP residues 214-659
|
未记录
|
AU GOLD ION × 4
|
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;pH 8.5;277 K;Mix purified dimer protein at 5 mg/ml in 25 mM TRIS.Cl, pH 8.5, 10 mM NaCl, 5 mM DTT with an equal volume of the precipitant solution, 100 mM TRIS.Cl, pH 8.5, 200 mM Na.acetate, 7.5 % PEG 4,000, then suspend over 1 ml of precipitant solution. Wedge shaped crystals grew to approximately 0.1 mm on a side after a period of two weeks. Crystals were frozen by first transferring them, in four sequential steps, to a solution of 100 mM TRIS.Cl, pH 8.5, 200 mM Na.acetate, 15 % PEG 4,000. This was followed by transfer in six sequential steps to a solution containing 100 mM TRIS.Cl, pH 8.5, 200 mM Na.acetate, 15 % PEG 4,000, 30% glucose
|
分辨率 2.60 Å
R-free 0.248
|
|
8FD9
Structure of BTK kinase domain with the second-generation inhibitor acalabrutinib
提交 2022-12-02
|
突变/修饰不同
配体/离子不同
实验环境不同
结构质量不同
|
Assembly 1
蛋白单体
单体;蛋白 × 1
PDB 声明:monomeric
|
链 A
396–659(264 aa)
|
突变:K430R, L542M S543T, V555T, R562K, S564A, P565S, Y617P
|
XQQ 4-[(4S)-8-amino-3-{(2S)-1-[(2E)-but-2-enoyl]pyrrolidin-2-yl}imidazo[1,5-a]pyrazin-1-yl]-N-(pyridin-2-yl)benzamide × 1
BR BROMIDE ION × 4
|
X-RAY DIFFRACTION
X-ray结晶条件
EVAPORATION;pH 6.5;277 K;20% PEG 3350, 0.1M Bis-tris propane, pH 6.5 and 0.2M sodium bromide
|
分辨率 1.70 Å
R-free 0.228
|
|
8FF0
Structure of BTK kinase domain with the second-generation inhibitor tirabrutinib
提交 2022-12-07
|
突变/修饰不同
配体/离子不同
实验环境不同
结构质量不同
|
Assembly 1
蛋白单体
单体;蛋白 × 1
PDB 声明:monomeric
|
链 A
396–659(264 aa)
|
突变:K430R, L542M S543T, V555T, R562K, S564A, P565S, Y617P
|
7GB 6-azanyl-9-[(3~{R})-1-[(~{E})-but-2-enoyl]pyrrolidin-3-yl]-7-(4-phenoxyphenyl)purin-8-one × 1
|
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 5.5;277 K;16% PEG 8000 and 0.1M sodium citrate
|
分辨率 2.60 Å
R-free 0.267
|
|
8GMB
Crystal structure of the full-length Bruton's tyrosine kinase (PH-TH domain not visible)
提交 2023-03-24
|
构建体不同
突变/修饰不同
聚集状态不同
配体/离子不同
实验环境不同
结构质量不同
|
Assembly 1
蛋白同源多聚体
同源多聚体;蛋白 × 2
PDB 声明:dimeric
|
链 A
1–659(659 aa)
|
突变:E298A, K300A, E301A, A384P, S386P, T387P, A388P, L390F, K430R, L542M S543T, V555T, R562K, S564A, P565S, Y617P
|
9AJ 2-[3'-(hydroxymethyl)-1-methyl-5-({5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl}amino)-6-oxo[1,6-dihydro[3,4'-bipyridine]]-2'-yl]-7,7-dimethyl-3,4,7,8-tetrahydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one × 2
|
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION;pH 7.5;277.15 K;20% PEG 3350, 0.1M Bis-Tris Propane, 0.2M potassium thiocyanate
|
分辨率 3.40 Å
R-free 0.289
|
|
8S93
Crystal structure of the PH-TH/kinase complex of Bruton's tyrosine kinase
提交 2023-03-27
|
构建体不同
突变/修饰不同
配体/离子不同
实验环境不同
结构质量不同
|
Assembly 1
蛋白单体
单体;蛋白 × 1
PDB 声明:monomeric
|
链 A
1–171(171 aa)
片段:PHTH domain residues 1-171 and Kinase domain residues 396-659
链 A
396–659(264 aa)
片段:PHTH domain residues 1-171 and Kinase domain residues 396-659
|
突变:Q91A, I92A, I94A, I95A, K430R, L542M S543T, V555T, R562K, S564A, P565S, Y617P
突变:Q91A, I92A, I94A, I95A, K430R, L542M S543T, V555T, R562K, S564A, P565S, Y617P
|
9AJ 2-[3'-(hydroxymethyl)-1-methyl-5-({5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl}amino)-6-oxo[1,6-dihydro[3,4'-bipyridine]]-2'-yl]-7,7-dimethyl-3,4,7,8-tetrahydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one × 1
ZN ZINC ION × 1
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION;pH 5.6;277 K;20%PEG3350, 0.1M Bis-Tris, pH5.6, 0.2M magnesium chloride
|
分辨率 2.10 Å
R-free 0.246
|
|
8S9F
Crystal structure of the kinase domain of Bruton's Tyrosine Kinase bound to dasatinib
提交 2023-03-28
|
构建体不同
突变/修饰不同
聚集状态不同
配体/离子不同
实验环境不同
结构质量不同
|
Assembly 1
蛋白同源多聚体
同源多聚体;蛋白 × 2
PDB 声明:dimeric
|
链 A
382–659(278 aa)
链 B
382–659(278 aa)
|
突变:L390G, Y551E, Y617P
突变:L390G, Y551E, Y617P
|
1N1 N-(2-CHLORO-6-METHYLPHENYL)-2-({6-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]-2-METHYLPYRIMIDIN-4-YL}AMINO)-1,3-THIAZOLE-5-CARBOXAMIDE × 2
|
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 7.5;277 K;42% PEG200, 0.1M HEPES
|
分辨率 2.60 Å
R-free 0.284
|
|
9EJJ
Bruton's tyrosine kinase in complex with compound PTI55
提交 2024-11-28
|
构建体不同
突变/修饰不同
配体/离子不同
实验环境不同
结构质量不同
|
Assembly 1
蛋白单体
单体;蛋白 × 1
PDB 声明:monomeric
|
链 A
382–659(278 aa)
|
突变:L390G, Y551E, Y617P
|
A1BIZ 4-{4-amino-1-[(3R)-1-(cyclopropanecarbonyl)piperidin-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}-N-[4-(trifluoromethoxy)pyridin-2-yl]benzamide × 1
|
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;277 K;0.1M NaCitrate pH 5.5, 18% PEG3350
|
分辨率 2.03 Å
R-free 0.242
|
|
9EJJ
Bruton's tyrosine kinase in complex with compound PTI55
提交 2024-11-28
|
构建体不同
突变/修饰不同
配体/离子不同
实验环境不同
结构质量不同
|
Assembly 2
蛋白单体
单体;蛋白 × 1
PDB 声明:monomeric
|
链 B
382–659(278 aa)
|
突变:L390G, Y551E, Y617P
|
A1BIZ 4-{4-amino-1-[(3R)-1-(cyclopropanecarbonyl)piperidin-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}-N-[4-(trifluoromethoxy)pyridin-2-yl]benzamide × 1
|
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;277 K;0.1M NaCitrate pH 5.5, 18% PEG3350
|
分辨率 2.03 Å
R-free 0.242
|
|
9EJR
Bruton's tyrosine kinase in complex with compound PTI52
提交 2024-11-28
|
构建体不同
突变/修饰不同
实验环境不同
结构质量不同
|
Assembly 1
蛋白单体
单体;蛋白 × 1
PDB 声明:monomeric
|
链 A
382–659(278 aa)
|
突变:L390G, Y551E, Y617P
|
A1BI0 4-{4-amino-1-[(3R)-1-(cyclopropanecarbonyl)piperidin-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}-N-(4-cyclopropylpyridin-2-yl)benzamide × 1
|
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;277 K;0.1M NaCitrate pH 5.5, 18% PEG3350
|
分辨率 2.10 Å
R-free 0.295
|
|
9EJR
Bruton's tyrosine kinase in complex with compound PTI52
提交 2024-11-28
|
构建体不同
突变/修饰不同
实验环境不同
结构质量不同
|
Assembly 2
蛋白单体
单体;蛋白 × 1
PDB 声明:monomeric
|
链 B
382–659(278 aa)
|
突变:L390G, Y551E, Y617P
|
A1BI0 4-{4-amino-1-[(3R)-1-(cyclopropanecarbonyl)piperidin-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}-N-(4-cyclopropylpyridin-2-yl)benzamide × 1
|
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;277 K;0.1M NaCitrate pH 5.5, 18% PEG3350
|
分辨率 2.10 Å
R-free 0.295
|
|
9EJX
Bruton's tyrosine kinase with mutations in the activation loop in complex with compound PTI42
提交 2024-11-29
|
突变/修饰不同
配体/离子不同
实验环境不同
结构质量不同
|
Assembly 1
蛋白单体
单体;蛋白 × 1
PDB 声明:monomeric
|
链 A
396–659(264 aa)
|
突变:K430R, L542M, S543T, V555T, R562K, S564A, P565S,Y617P
|
A1BI1 {(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl}(cyclopropyl)methanone × 1
|
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;277 K;0.1 M Sodium citrate tribasic dihydrate pH 5.5, 18% w/v Polyethylene glycol 8,000
|
分辨率 2.86 Å
R-free 0.296
|
|
9ME2
Bruton's tyrosine kinase with mutations in the activation loop in complex with compound A110162
提交 2024-12-05
|
突变/修饰不同
配体/离子不同
实验环境不同
结构质量不同
|
Assembly 1
蛋白单体
单体;蛋白 × 1
PDB 声明:monomeric
|
链 A
396–659(264 aa)
|
突变:K430R, L542M, S543T, V555T, R562K, S564A, P565S,Y617P
|
A1BKW 3-(4-phenoxyphenyl)-1-[(3S)-piperidin-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine × 1
|
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;277 K;0.1 M Sodium citrate tribasic dihydrate pH 5.5, 18% w/v Polyethylene glycol 8,000
|
分辨率 3.38 Å
R-free 0.286
|
|
9ME3
Bruton's tyrosine kinase with mutations in the activation loop in complex with compound P301390
提交 2024-12-06
|
突变/修饰不同
配体/离子不同
实验环境不同
结构质量不同
|
Assembly 1
蛋白单体
单体;蛋白 × 1
PDB 声明:monomeric
|
链 A
396–659(264 aa)
|
突变:K430R, L542M, S543T, V555T, R562K, S564A, P565S,Y617P
|
A1BJE 3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine × 1
|
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;277 K;0.1 M Sodium citrate tribasic dihydrate pH 5.5, 18% w/v Polyethylene glycol 8,000
|
分辨率 3.05 Å
R-free 0.288
|
|
9ZLJ
Crystal structure of BTK kinase domain bound to compound YS1
提交 2025-12-08
|
构建体不同
突变/修饰不同
配体/离子不同
实验环境不同
结构质量不同
|
Assembly 1
蛋白单体
单体;蛋白 × 1
PDB 声明:monomeric
|
链 A
382–659(278 aa)
|
突变:Y617P
|
A1C20 N-{(1r,4r)-4-[2-(4-chlorophenoxy)acetamido]cyclohexyl}-N-[2-(4-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)ethyl]propanamide × 1
IMD IMIDAZOLE × 1
|
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;15-25% PEG3350, 0.1M imidazole
|
分辨率 1.60 Å
R-free 0.218
|
|
9ZLM
Crystal structure of BTK kinase domain bound to compound YS2
提交 2025-12-08
|
构建体不同
突变/修饰不同
配体/离子不同
实验环境不同
结构质量不同
|
Assembly 1
蛋白单体
单体;蛋白 × 1
PDB 声明:monomeric
|
链 A
382–659(278 aa)
|
突变:Y617P
|
A1C2Z N-[4-(3-{2-oxo-2-[3-(phenoxymethyl)azetidin-1-yl]acetamido}phenyl)oxan-4-yl]propanamide × 1
IMD IMIDAZOLE × 1
|
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;15-25% PEG3350, 0.1M imidazole
|
分辨率 1.27 Å
R-free 0.212
|